[May 02, 2014] |
|
Research and Markets: Smoking Cessation Therapeutics Pipeline Review 2014 - Detailing 16 Companies & 25 Drug Profiles
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/7ndsd4/smoking_cessation)
has announced the addition of the "Smoking
Cessation - Pipeline Review, H1 2014" report to their offering.
This report provides comprehensive information on the therapeutic
development for Smoking Cessation, complete with comparative analysis at
various stages, therapeutics assessment by drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type, along
with latest updates, and featured news and press releases. It also
reviews key players involved in the therapeutic development for Smoking
Cessation and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.
Scope
-
The report provides a snapshot of the global therapeutic landscape of
Smoking Cessation
-
The report reviews key pipeline products under drug profile section
which includes, product description, MoA andR&D brief, licensing and
collaboration details & other developmental activities
-
The report reviews key players involved in the therapeutics
development for Smoking Cessation and enlists all their major and
minor projects
-
The report summarizes all the dormant and discontinued pipeline
projects
-
A review of the Smoking Cessation products under development by
companies and universities/research institutes based on information
derived from company and industry-specific sources
-
Pipeline products coverage based on various stages of development
ranging from pre-registration till discovery and undisclosed stages
-
A detailed assessment of monotherapy and combination therapy pipeline
projects
-
Coverage of the Smoking Cessation pipeline on the basis of target,
MoA, route of administration and molecule type
-
Latest news and deals relating related to pipeline products
Companies Involved in Therapeutics Development
-
Johnson & Johnson
-
Aradigm Corporation
-
GlaxoSmithKline plc
-
Pfizer Inc.
-
Arena Pharmaceuticals, Inc.
-
Targacept, Inc.
-
Invion Limited
-
Marinus Pharmaceuticals, Inc.
-
Royalty Pharma
-
Selecta Biosciences, Inc.
-
Embera NeuroTherapeutics, Inc.
-
NAL Pharmaceuticals Ltd.
-
BIOPROJET SCR
-
Astraea Therapeutics, LLC
-
Adial Pharmaceuticals, LLC
-
Istituto Italiano di Tecnologia
Drug Profiles
-
GSK-598809
-
lorcaserin hydrochloride
-
nadolol
-
ganaxolone
-
cycloserine
-
BP-1.4979
-
meclizine hydrochloride
-
zonisamide
-
ARD-1600
-
(oxazepam + metyrapone)
-
ondansetron
-
SEL-068
-
PF-05402536
-
PF-06413367
-
cycloserine
-
Small Molecule for Smoking Cessation
-
nicotine
-
NIC7-DT
-
CC-4
-
Small Molecules to Inhibit Nicotinic Acetylcholine Receptor for
Smoking Cessation
-
Small Molecule for Smoking Cessation
-
Alpha 4 Beta 2 Neuronal Nicotinic Receptor Agonists for Smoking
Cessation
-
Small Molecules to Inhibit FAAH for CNS Disorders
-
Nicotine Vaccine
-
NAL-2762
For more information visit http://www.researchandmarkets.com/research/7ndsd4/smoking_cessation
[ Back To TMCnet.com's Homepage ]
|